文献速递老年慢病共病管理衰弱、肌少症与跌倒

阿司匹林对社区老年人健康寿命的影响:ASPREE研究

Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study.
PubMed 文献 · Age Ageing · 2026-01-01

ASPREE是一项双盲、安慰剂对照随机试验,评估每日低剂量阿司匹林(100 mg)对社区居住老年人健康寿命丧失的影响。结论认为低剂量阿司匹林对健康寿命丧失率无影响。

要点

  • 每日100 mg阿司匹林未降低社区老年人健康寿命丧失风险。
  • 健康寿命丧失定义为心血管病、糖尿病、痴呆、癌症或死亡首次发生。
  • 阿司匹林组与安慰剂组健康寿命丧失率相近,无显著差异。

核心结论

  • 低剂量阿司匹林对社区居住老年人的健康寿命丧失率无影响。

研究设计与样本

  • ASPREE为双盲、安慰剂对照随机试验,评估每日低剂量阿司匹林用于一级预防的效果。
  • 从澳大利亚和美国招募≥70岁(美国少数族裔≥65岁)社区居住、初始无重大疾病且预期寿命超过5年的参与者。

主要发现

  • 5835名参与者(30.5%)发生健康寿命丧失。
  • 年龄较大、男性、吸烟、高血压或衰弱者更易发生健康寿命丧失。
  • 阿司匹林组和安慰剂组健康寿命丧失率分别为82.1和82.7事件/1000人年。
  • 阿司匹林组与安慰剂组健康寿命丧失风险无显著差异(HR 0.98;95%CI 0.92-1.05)。

临床怎么用

  • 对于社区居住的老年人,不应期望通过每日低剂量阿司匹林来延长健康寿命。
  • 未来研究应探索生活方式和行为干预以延长健康寿命。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammation is a shared pathogenic pathway underlying multiple chronic conditions and contributes to a loss of healthspan. This study aimed to evaluate the effect of low-dose aspirin on the loss of healthspan in older individuals. METHODS: ASPirin in Reducing Events in the Elderly (ASPREE) was a double-blind, placebo-controlled, randomised trial assessing the effect of daily low-dose aspirin for primary prevention. Community-dwelling participants aged ≥70 years [or ≥ 65 years for United States (US) minority ethnic groups] were recruited from Australia and the US. Eligible participants were initially free of major diseases with a life expectancy of more than five years and were randomly assigned to receive 100 mg of aspirin daily or a placebo. Loss of healthspan was defined as the first occurrence of cardiovascular disease, diabetes, dementia, cancer, or death. RESULTS: A total of 19 114 participants were followed for a median of 4.7 years, 5835 participants (30.5%) experienced a loss of healthspan. Participants who were older, male, smokers, or had hypertension, or frailty were more likely to experience healthspan loss during the trial. The rate of healthspan loss was 82.1 and 82.7 events per 1000 person-years in the aspirin and placebo groups, respectively. There was no evidence of a substantial difference in the risk of healthspan loss between the aspirin and placebo groups (hazard ratio, 0.98; 95% CI: 0.92-1.05). CONCLUSION: Low-dose aspirin had no effect on the rate of loss of healthspan among older community-dwelling adults. Future studies should explore lifestyle and behavioural interventions to extend healthspan.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Zheng HT, Phyo AZZ, Wu Z, et al. Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study. Age Ageing. 2026. PMID: 42497096. doi:10.1093/ageing/afag218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。